Modulation of atherosclerosis, blood pressure and arterial elasticity by statins

Advances in Cardiology

Volumn 44, Issue , 2007, Pages 315-330

  Sinha, Anjan K ^a   Mehta, Jawahar L ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; BLOOD PRESSURE; DRUG EFFECT; DYSLIPIDEMIA; ELASTICITY; HUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ATHEROSCLEROSIS; BLOOD PRESSURE; DYSLIPIDEMIAS; ELASTICITY; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RENIN-ANGIOTENSIN SYSTEM; VASCULAR RESISTANCE;

EID: 33751109469     PISSN: 00652326     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096750     Document Type: Review

References (53)

1. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK: Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-43.
2. McEwen JE, Zimniak P, Mehta JL, Reis RJ: Molecular pathology of aging and its implications for senescent coronary atherosclerosis. Curr Opin Cardiol 2005;20:399-406.
3. Scandinavian Simvastatin Survival Study (4S): Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994;344:1383-1389.
4. West of Scotland Coronary Prevention Study (WOSCOPS): Influence of pravastatin and plasma lipids on clinical events in the WOSCOPS. Circulation 1998;97:1440-1445.
5. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F: Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001;289:857-861.
6. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
7. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-2134.
8. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Guttierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
9. Holstein SA, Wohlford-Lenane CL, Hohl RJ: Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 2002;277:10678-10682.
10. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cotten S, Takada Y, Hommel U: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-692.
11. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, Kita T: Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;83:322-327.
12. Mehta JL, Li DY: Identification, regulation and function of LOX-1, a novel receptor for ox-LDL. J Am Coll Cardiol 2002;39:1429-1435.
13. Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T: LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 2000;467:217-220.
14. Li DY, Chen HJ, Mehta JL: Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001;52:130-135.
15. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL: LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-617.
16. Cola C, Almeida M, Li D, Romeo F, Mehta JL: Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun 2004;320:424-427.
17. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D: Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000;96:4212-4215.
18. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U: Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor-α-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003;14:575-585.
19. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B: Simvastatin prevents angiotensin II-in-duced cardiac alteration and oxidative stress. Hypertension 2002;40:142-147.
20. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-736.
21. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
22. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
23. Li DY, Chen HJ, Romeo F, Sawamura T, Saldeen T, Mehta JL: Statins modulate ox-LDL-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Cardiovasc Pharmacol Ther 2002;302:601-605.
24. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935.
25. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
26. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-484.
27. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999.
28. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G: Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-985.
29. Maeda T, Matsunuma A, Kawane T, Horiuchi N: Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001;280:874-877.
30. Keidar S, Heinrich R, Kaplan M, Aviram M: Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages. J Renin Angiotensin Aldosterone Syst 2002;3:24-30.
31. Singh BK, Sinha AK, Mehta JL: Statins in the primary prevention of atherosclerosis-related events; in Mehta JL (ed): Statins: Understanding Clinical Use. Philadelphia, Saunders 2004.
32. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL: Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999;84:1043-1049.
33. Sung BH, Izzo JL Jr, Wilson MF: Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997;10:592-599.
34. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-725.
35. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M: Statin-sensitive dysregulated ATI receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-2134.
36. Vidal F, Colome C, Martinez-Gonzalez J, Badimon L: Atherogenic concentrations of native low-density lipoproteins down-regulate nitric oxide synthase mRNA and protein levels in endothelial cells. Eur J Biochem 1998;252:378-384.
37. Kotchen TA, Talwalkar RT: Increased enzymatic activity of renin and hyperlipidemia. Am J Physiol 1981;240:E60-E64.
38. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG, Louis WJ: Short-term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994;3:404-406.
39. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-1499.
40. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-555.
41. Schmalfuss CM, Chen LY, Bott JN, Staples ED, Mehta JL: Superoxide anion generation, superoxide dismutase activity, and nitric oxide release in human internal mammary artery and saphenous vein segments. J Cardiovasc Pharmacol Ther 1999;4:249-257.
42. Cooke JP: NO and angiogenesis. Atheroscler Suppl 2003;4:53-60.
43. Deckend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation 2001;104:576-581.
44. Patel R, Nagueh SF, Tsybouleva N, et al: Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324.
45. Reddy R, Chahoud G, Mehta JL: Modulation of cardiovascular remodeling with statins: fact or fiction? Curr Vasc Pharmacol 2005;3:69-79.
46. Daugherty A, Cassis L: Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann NY Acad Sci 1999;892:108-118.
47. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T: Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005;19:103-109.
48. Raison J, Rudnichi A, Safar ME: Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002;16:705-710.
49. Abetel G, Poget PN, Bonnabry JP: Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz Med Wochenschr 1998;128:272-277.
50. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1286.
51. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-1895.
52. Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitriadis DS, Papageorgiou AA, Boudoulas H: Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003;19:22-27.
53. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA: Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-1025.